September 16, 2011
Emerald BioStructures Initiates Collaboration With Cephalon
Bainbridge Island, WA, September 16, 2011. Emerald BioStructures, Inc., announces the intiation of a new research collaboration with Cephalon to obtain antibody-antigen co-crystal structures. The milestone based research collaboration provides Cephalon access to Emerald's rapid high-throughput crystallization platform and Emerald's biophysical tool set for characterization of protein-protein interactions.
About Emerald BioStructures:
Emerald BioStructures is an integrated gene-to-structure contract research organization that provides collaborative drug discovery services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. The company operates a high-throughput platform leveraged for fragment-based lead discovery and structure-based drug design. Emerald's work provides a solid foundation for the discovery of highly selective, efficacious drugs. www.emeraldbiostructures.com